CBO calls for new research in the area of obesity

The US Congressional Budget Office (CBO) is on the lookout for new research that would enhance its analysis of policies affecting the use of obesity treatments - especially research on the use of anti-obesity medications (AOMs).

The developing market for AOMs could significantly affect health care spending and the federal budget. The most recent available data show that spending on AOMs has increased markedly. The CBO has not yet produced a cost estimate for legislation that would expand access to those medications for beneficiaries of government programs such as Medicare, but the agency is monitoring trends in the use of AOMs, along with their prices, effects on health, and coverage by insurance plans.

Recent trends in the availability and use of anti-obesity meds